Evidence map›Paper›PMID 35999575›Full record

ArticleMicrobiome2022

Location-specific signatures of Crohn's disease at a multi-omics scale.

Carlos G Gonzalez, Robert H Mills, Qiyun Zhu, Consuelo Sauceda, Rob Knight, Parambir S Dulai, David J Gonzalez

Open access · goldAbstract readVideo-Audio Media
In one paragraph

Article in Microbiome, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed, 1 pooled it
17.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 1 synthesis or guideline pooled it, 94 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. New approach methodologies in Crohn's disease link molecular disease subtypes to clinical outcomes.American journal of physiology. Gastrointestinal and liver physiology · 2026
    Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Observational
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Carlos G GonzalezDepartment of Pharmacology, University of California San Diego, San Diego, CA, 92093, USA.
Robert H MillsDepartment of Pharmacology, University of California San Diego, San Diego, CA, 92093, USA.
Qiyun ZhuSchool of Life Sciences, Arizona State University, Tempe, AZ, USA.
Consuelo SaucedaDepartment of Pharmacology, University of California San Diego, San Diego, CA, 92093, USA.
Rob KnightDepartment of Pediatrics, University of California San Diego, San Diego, CA, 92093, USA.
Parambir S DulaiDepartment of Medicine, Division of Gastroenterology and Hepatology, Feinberg School of Medicine Northwestern University, Chicago, IL, 60061, USA. parambir.dulai@northwestern.edu.
David J GonzalezDepartment of Pharmacology, University of California San Diego, San Diego, CA, 92093, USA. djgonzalez@health.ucsd.edu.
University of California, San Diego · USArizona State University · USNorthwestern University · USUniversity of San Diego · US

Funding

UCSD/SDSU IRACDAK12GM068524 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI TREJO, JOANN · 2003 to 2025
$24.4M
San Diego Digestive Diseases Research CenterP30DK120515 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Tatiana Kisseleva · 2019 to 2026
$10.8M
Microbiome Driven Proteolysis as a Contributing Factor to Severity of Ulcerative Colitis Disease ActivityR01DK131005 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GONZALEZ, DAVID J · 2022 to 2024
$1.6M
NIDDK NIH HHS P30 DK120515NIDDK NIH HHS R01 DK131005NIGMS NIH HHS K12 GM068524
6 · The paper itself

Abstract

backgroundCrohn's disease (CD), an inflammatory bowel disease (IBD) subtype, results from pathologic interactions between host cells and its resident gut microbes. CD manifests in both isolated disease locations (ileum or colon) or a combination of locations (ileocolonic). To date, a comprehensive understanding of how isolated CD subtypes influence molecular profiles remains outstanding. To address this, we sought to define CD location signatures by leveraging a large cross-sectional feature set captured from the stool of over 200 IBD patients and healthy controls using metaproteomics, shotgun metagenomics, 16S rRNA sequencing, metabolomic profiling, and host genetics paired with clinical endoscopic assessments.

resultsNeither metagenomic nor host genetics alone distinguished CD location subtypes. In contrast, ileal and colonic CD were distinguished using mass spectrometry-based methods (metabolomics or metaproteomics) or a combined multi-omic feature set. This multi-omic feature set revealed colonic CD was strongly associated with neutrophil-related proteins. Additionally, colonic CD displayed a disease-severity-related association with Bacteroides vulgatus. Colonic CD and ulcerative colitis profiles harbored strikingly similar feature enrichments compared to ileal CD, including neutrophil-related protein enrichments. Compared to colonic CD, ileal CD profiles displayed increased primary and secondary bile acid levels and concomitant shifts in taxa with noted sensitivities such as Faecalibacterium prausnitzii or affinities for bile acid-rich environments, including Gammaproteobacteria and Blautia sp. Having shown robust molecular and microbial distinctions tied to CD locations, we leveraged these profiles to generate location-specific disease severity biomarkers that surpass the performance of Calprotectin.

conclusionsWhen compared using multi-omics features, colonic- and ileal-isolated CD subtypes display striking differences that suggest separate location-specific pathologies. Colonic CD's strong similarity to ulcerative colitis, including neutrophil and Bacteroides vulgatus involvement, is also evidence of a shared pathology for colonic-isolated IBD subtypes, while ileal CD maintains a unique, bile acid-driven profile. More broadly, this study demonstrates the power of multi-omics approaches for IBD biomarker discovery and elucidating the underlying biology. Video Abstract.

Indexed as

Crohn DiseaseBacteroidesBile Acids and SaltsCross-Sectional StudiesFecesHumansMetagenomicsRNA, Ribosomal, 16SBile Acids and SaltsRNA, Ribosomal, 16SColonic Crohn’sCrohn’s diseaseIleal Crohn’sInflammatory bowel diseaseMicrobiomeMulti-omics

Identifiers

PMID35999575
PMCPMC9400277
OpenAlexW4293030232

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.